<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69055">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206841</url>
  </required_header>
  <id_info>
    <org_study_id>NAFLD_cohort</org_study_id>
    <nct_id>NCT02206841</nct_id>
  </id_info>
  <brief_title>Establishment of NAFLD Cohort and Development of Fibrosis Markers</brief_title>
  <acronym>NAFLD</acronym>
  <official_title>Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Boramae Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Boramae Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed for establishment of non-alcoholic fatty liver disease patients
      cohort to development of markers to predict histologic progression of liver fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Acoustic radiation force impulse elastography

        -  Liver tissue (frozen tissue, paraffin block)

        -  Whole blood, Serum

        -  Fat amount ratio CT (Visceral adipose tissue, Subcutaneous adipose tissue amount)

        -  Body composition analyzer (InBody scale):Total fat/muscle mass and appendicular
           skeletal muscle mass
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>histologic steatosis and fibrosis grade</measure>
    <time_frame>baseline</time_frame>
    <description>We will evaluate fibrosis using laboratory examination, radiologic evaluation and liver tissue pathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of markers for hepatic fibrosis progression</measure>
    <time_frame>baseline and every 6 months (up to 1year)</time_frame>
    <description>We will analysis and development fibrosis markers by obtained blood sample and liver tissue,</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Fibrosis of Liver</condition>
  <arm_group>
    <arm_group_label>NAFLD</arm_group_label>
    <description>Patients with suspected nonalcoholic fatty liver disease will be screened. Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained. In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed. A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis. Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study. Several serum and plasma samples are collected of patients and stored for future analysis such as super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, and metabolomics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <description>Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.</description>
    <arm_group_label>NAFLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARFI</intervention_name>
    <description>Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.</description>
    <arm_group_label>NAFLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SWE</intervention_name>
    <description>Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.</description>
    <arm_group_label>NAFLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transient elastography (Fibroscan)</intervention_name>
    <description>Transient elastography will be performed for evaluate fibrosis of liver.</description>
    <arm_group_label>NAFLD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Obtained blood samples will be stored by serum and plasma for future analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Non-alcoholic fatty liver disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed fatty liver disease

          -  Patients with radiologically confirmed fatty liver disease

        Exclusion Criteria:

          -  History of significant alcohol consumption

          -  Viral hepatitis

          -  Autoimmune hepatitis

          -  Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)

          -  Hepatotoxic medication (e.g. amiodarone)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Won Kim, MD,PhD</last_name>
    <phone>8228702233</phone>
    <email>drwon1@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saekyung Joo, MD</last_name>
    <phone>821089619285</phone>
    <email>joo.sammy@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul Metropolitan Government Seoul National University</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Kim, MD, PhD</last_name>
      <phone>8228702233</phone>
      <email>drwon1@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Won Kim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology. 2009 Jun;49(6):1913-25. doi: 10.1002/hep.22887.</citation>
    <PMID>19378344</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 24, 2016</lastchanged_date>
  <firstreceived_date>July 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Boramae Hospital</investigator_affiliation>
    <investigator_full_name>Won Kim</investigator_full_name>
    <investigator_title>M.D, PhD</investigator_title>
  </responsible_party>
  <keyword>fibrosis</keyword>
  <keyword>markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
